{"id":451723,"date":"2021-03-05T08:33:30","date_gmt":"2021-03-05T13:33:30","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=451723"},"modified":"2021-03-05T08:33:30","modified_gmt":"2021-03-05T13:33:30","slug":"immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/","title":{"rendered":"Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>&#8212; Plans to initiate four Phase 2 trials in second half of 2021&#8211;<\/em><br \/>\n        \n      <\/p>\n<p align=\"center\">\n        <em>&#8212; Exploring additional autoimmune and allergic disease indications for portfolio candidates &#8212;<\/em>\n      <\/p>\n<p align=\"justify\">NEW ORLEANS and LONDON, March  05, 2021  (GLOBE NEWSWIRE) &#8212; Immune Regulation today announced it is rebranding as Revolo Biotherapeutics (\u201cRevolo Bio\u201d). The new brand, which will be implemented immediately, comes ahead of the advancement of the Company\u2019s drug candidates into five clinical programs, including four Phase 2 trials.<\/p>\n<p align=\"justify\">The new brand better reflects the Company\u2019s revolutionary approach to developing therapies that reset the immune system with the goal of achieving superior long-term disease remission for patients with autoimmune and allergic diseases. Revolo Bio\u2019s drug candidates, \u20181805 and \u20181104, have already demonstrated efficacy and safety in both preclinical and human studies while preventing the unwanted effects of chronic immune suppression. Revolo Bio will advance \u20181805 through two Phase 2 trials for patients with moderate-to-severe rheumatoid arthritis and for patients with non-infectious uveitis. Additionally, Revolo Bio is advancing a Phase 2 trial of \u20181104 for patients with eosinophilic esophagitis (EoE) and a Phase 2 allergen sensitivity study. In addition, Revolo Bio recently initiated an additional Phase 1 study of \u20181104 designed to evaluate the safety of ascending doses in healthy volunteers to support future Phase 2 clinical trials.<\/p>\n<p align=\"justify\">\u201cRevolo Biotherapeutics reflects our focused mission to reset the immune system to achieve long-term disease remission of autoimmune and allergic disease,\u201d said Jonathan Rigby, Group Chief Executive Officer of Revolo Biotherapeutics. \u201cWe are advancing four Phase 2 clinical programs with multiple near-term readouts occurring, and we believe that the unique, disease-agnostic mechanisms of action of our drug candidates creates vast optionality across multiple indications. Our team of successful industry professionals and immunology and allergic disease experts is rapidly growing to include more dedicated revolutionizers ready to support our upcoming milestones.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About Revolo Biotherapeutics <\/strong><br \/>\n        <br \/>Revolo Biotherapeutics is developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic disease, without the immune system suppression seen with current therapies. Its two drug candidates, \u20181805 and \u20181104, a protein and a peptide respectively, reset the immune system by preventing the chronic pro-inflammatory immune response that results in autoimmune or allergic disease. \u20181805 is a modified analogue of a key protein in immune function and is entering clinical development for moderate-to-severe rheumatoid arthritis and non-infectious uveitis. \u20181104 is a peptide derived from a natural immune-regulatory protein and is entering clinical development for patients with eosinophilic esophagitis (EoE) and allergic disease. The disease-agnostic mechanism of action of Revolo Biotherapeutic\u2019s assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases.<\/p>\n<p align=\"justify\">For further information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vPwTFnmvKnMGnbue1rccruJ8Ccxych8b4u0t3kEhcLnns7hTTyslFq0X5zNG_s3vjuIYGKB702Z1bXKwaT2JwQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.revolobio.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Company Contact<\/strong><br \/>\n        <br \/>Marylyn Rigby, VP Investor Relations &amp; Marketing <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xj0kMv0CEtK6ZSf6ryCFdVBgoHx4qk5YYgCSCkGzuP62SnyjAIQ5aDFsfCLkE1HA9lr-BOe1H_FL8AqlWBfaOSjt3m8GaamD6JxCvNV-LKY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>mrigby@revolobio.com<\/u><\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact <\/strong><br \/>\n        <br \/>Monica Rouco Molina, Ph.D.<br \/>LifeSci Communications<br \/>+1-929-469-3850<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P5HukX5Aomo1mAaWAxgHL5Zh4O6IVcBe9GEUV_tzVxPPONvjEnmG28O-Yyixs-QEKxeIDjjc3kzxtyoObso5kxp73nzZwqJT9npieew_sxcf3-ePOoPFsXYYK0to4KJb\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mroucomolina@lifescicomms.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTA2MCM0MDQ5MjU3IzUwMDA3NjgyNQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/2cd963af-d79b-42cd-9c00-c9c6d51668fc\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8212; Plans to initiate four Phase 2 trials in second half of 2021&#8211; &#8212; Exploring additional autoimmune and allergic disease indications for portfolio candidates &#8212; NEW ORLEANS and LONDON, March 05, 2021 (GLOBE NEWSWIRE) &#8212; Immune Regulation today announced it is rebranding as Revolo Biotherapeutics (\u201cRevolo Bio\u201d). The new brand, which will be implemented immediately, comes ahead of the advancement of the Company\u2019s drug candidates into five clinical programs, including four Phase 2 trials. The new brand better reflects the Company\u2019s revolutionary approach to developing therapies that reset the immune system with the goal of achieving superior long-term disease remission for patients with autoimmune and allergic diseases. Revolo Bio\u2019s drug candidates, \u20181805 and \u20181104, have already demonstrated efficacy and safety &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-451723","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8212; Plans to initiate four Phase 2 trials in second half of 2021&#8211; &#8212; Exploring additional autoimmune and allergic disease indications for portfolio candidates &#8212; NEW ORLEANS and LONDON, March 05, 2021 (GLOBE NEWSWIRE) &#8212; Immune Regulation today announced it is rebranding as Revolo Biotherapeutics (\u201cRevolo Bio\u201d). The new brand, which will be implemented immediately, comes ahead of the advancement of the Company\u2019s drug candidates into five clinical programs, including four Phase 2 trials. The new brand better reflects the Company\u2019s revolutionary approach to developing therapies that reset the immune system with the goal of achieving superior long-term disease remission for patients with autoimmune and allergic diseases. Revolo Bio\u2019s drug candidates, \u20181805 and \u20181104, have already demonstrated efficacy and safety &hellip; Continue reading &quot;Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-05T13:33:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTA2MCM0MDQ5MjU3IzUwMDA3NjgyNQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases\",\"datePublished\":\"2021-03-05T13:33:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\\\/\"},\"wordCount\":481,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NTA2MCM0MDQ5MjU3IzUwMDA3NjgyNQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\\\/\",\"name\":\"Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NTA2MCM0MDQ5MjU3IzUwMDA3NjgyNQ==\",\"datePublished\":\"2021-03-05T13:33:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NTA2MCM0MDQ5MjU3IzUwMDA3NjgyNQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NTA2MCM0MDQ5MjU3IzUwMDA3NjgyNQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/","og_locale":"en_US","og_type":"article","og_title":"Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases - Market Newsdesk","og_description":"&#8212; Plans to initiate four Phase 2 trials in second half of 2021&#8211; &#8212; Exploring additional autoimmune and allergic disease indications for portfolio candidates &#8212; NEW ORLEANS and LONDON, March 05, 2021 (GLOBE NEWSWIRE) &#8212; Immune Regulation today announced it is rebranding as Revolo Biotherapeutics (\u201cRevolo Bio\u201d). The new brand, which will be implemented immediately, comes ahead of the advancement of the Company\u2019s drug candidates into five clinical programs, including four Phase 2 trials. The new brand better reflects the Company\u2019s revolutionary approach to developing therapies that reset the immune system with the goal of achieving superior long-term disease remission for patients with autoimmune and allergic diseases. Revolo Bio\u2019s drug candidates, \u20181805 and \u20181104, have already demonstrated efficacy and safety &hellip; Continue reading \"Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-05T13:33:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTA2MCM0MDQ5MjU3IzUwMDA3NjgyNQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases","datePublished":"2021-03-05T13:33:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/"},"wordCount":481,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTA2MCM0MDQ5MjU3IzUwMDA3NjgyNQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/","name":"Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTA2MCM0MDQ5MjU3IzUwMDA3NjgyNQ==","datePublished":"2021-03-05T13:33:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTA2MCM0MDQ5MjU3IzUwMDA3NjgyNQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTA2MCM0MDQ5MjU3IzUwMDA3NjgyNQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immune-regulation-announces-rebranding-to-revolo-biotherapeutics-reflecting-a-revolutionary-approach-to-resetting-the-immune-system-to-treat-autoimmune-and-allergic-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=451723"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451723\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=451723"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=451723"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=451723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}